O Conort1, V Siguret2, O Bourdon3, S Nazaraly4, M Brignone4, N Pons-Kerjean5, S Houze6, S Laribe Cage7, F Berthet8, J-L Golmard9, F Brion3, P Tilleul10. 1. Service de pharmacie, hôpital Cochin, AP-HP, 27, rue du Faubourg-Saint-Jacques, 75679 Paris, France. Electronic address: ornella.conort@cch.aphp.fr. 2. Service d'hématologie biologique, hôpital européen Georges-Pompidou, AP-HP, 75908 Paris, France; Inserm UMR-S-1140, faculté de pharmacie, université Paris Descartes, 75270 Paris, France. 3. Service de pharmacie, hôpital Robert-Debré, AP-HP, 75935 Paris, France; Pharmacie clinique, faculté de pharmacie, université Paris Descartes, 75270 Paris, France. 4. Service de pharmacie, hôpital Saint-Antoine, AP-HP, 75571 Paris, France. 5. Service de pharmacie, hôpital Beaujon, AP-HP, 92110 Paris, France. 6. Laboratoire de parasitologie, hôpital Bichat-Claude-Bernard, AP-HP, 75877 Paris, France. 7. Service de pharmacie, hôpital Rothschild, AP-HP, 75012 Paris, France. 8. Service de pharmacie, hôpitaux de Saint-Maurice, 94410 Saint-Maurice, France. 9. Département de biostatistiques, GH Pitié-Salpêtrière, AP-HP, 75651 Paris, France. 10. Pharmacie clinique, faculté de pharmacie, université Paris Descartes, 75270 Paris, France; Service de pharmacie, GH Pitié-Salpêtrière, AP-HP, 75651 Paris, France.
Abstract
INTRODUCTION: We developed a training program for pharmacy students aiming at supporting patients receiving vitamin K antagonists (VKAs). The objective was to estimate how the program impacts VKA-treated patient knowledge acquisition and/or improvement on their anticoagulant treatment. METHOD: Using dedicated tools, pharmacy students received education on VKA treatment. Once appointed to clinical wards of Assistance publique-Hôpitaux de Paris, they were in charge of evaluating patient's knowledge on VKA treatment before and after training. Evaluation was conducted using a face-to-face standardized interview (14-item questionnaire). A global score was calculated for each patient. An univariate and multivariate analysis was performed to identify potential variables influencing score result. RESULTS: One hundred and seventy VKA-treated patients were recruited in seven hospitals for evaluation of their knowledge on VKA treatment and on clinical at risk situations. Before intervention, patients obtained an average score of 12.3±3.2 (maximum: 18). Factors significantly associated with the score were possession of a VKA information booklet, VKA treatment duration, treatment initiation and age. Fifty-two patients with a low score were further trained by the pharmacy student. After intervention, their initial score was improved significantly, from 9.9±3.3 to 13.5±2.3 (P<0.0001). DISCUSSION AND CONCLUSION: Increasing patient knowledge is a way to decrease the rate of adverse effects. This study demonstrates that patients with primary poor knowledge improved it significantly thanks to pharmacy students' intervention. This may contribute to lower the VKA-associated risk of adverse events and consequently to the improvement of patients quality of life and healthcare expenditures.
INTRODUCTION: We developed a training program for pharmacy students aiming at supporting patients receiving vitamin K antagonists (VKAs). The objective was to estimate how the program impacts VKA-treated patient knowledge acquisition and/or improvement on their anticoagulant treatment. METHOD: Using dedicated tools, pharmacy students received education on VKA treatment. Once appointed to clinical wards of Assistance publique-Hôpitaux de Paris, they were in charge of evaluating patient's knowledge on VKA treatment before and after training. Evaluation was conducted using a face-to-face standardized interview (14-item questionnaire). A global score was calculated for each patient. An univariate and multivariate analysis was performed to identify potential variables influencing score result. RESULTS: One hundred and seventy VKA-treated patients were recruited in seven hospitals for evaluation of their knowledge on VKA treatment and on clinical at risk situations. Before intervention, patients obtained an average score of 12.3±3.2 (maximum: 18). Factors significantly associated with the score were possession of a VKA information booklet, VKA treatment duration, treatment initiation and age. Fifty-two patients with a low score were further trained by the pharmacy student. After intervention, their initial score was improved significantly, from 9.9±3.3 to 13.5±2.3 (P<0.0001). DISCUSSION AND CONCLUSION: Increasing patient knowledge is a way to decrease the rate of adverse effects. This study demonstrates that patients with primary poor knowledge improved it significantly thanks to pharmacy students' intervention. This may contribute to lower the VKA-associated risk of adverse events and consequently to the improvement of patients quality of life and healthcare expenditures.
Keywords:
Accompagnement thérapeutique; Antagonistes de la vitamine K; Patient education; Pharmacy student; Vitamin K antagonists; Étudiant en pharmacie